DMRA Stock Forecast & Price Target

Damora Therapeutics is attractive because DMR-001 has already entered the clinic, the FDA has cleared its IND, and CLARITY-101 is enrolling across multiple U.S. sites with more than 50 sites selected worldwide, giving the company a credible path to first-in-class or best-in-class differentiation in mutCALR-driven ET and MF. Its fundamental appeal is strengthened by strong preclinical potency across Type 1 and non-Type 1 variants, including a mean 95-fold improvement over a reference antibody in non-Type 1 variants, plus a monthly subcutaneous dosing profile that could be more convenient than competitors’ intravenous or more frequent regimens. Financially, Damora reported $528.5 million in cash, cash equivalents, and marketable securities, which management expects to fund operations into 2H 2029 and cover mid-2027 proof-of-concept readouts and a planned mid-2028 registrational start.

Damora Therapeutics is viewed negatively because its lead program faces major execution and competitive risks, including possible delays to clinic entry, manufacturing issues, slower enrollment, and regulatory requests that could push the mid-2027 Ph 1 POC readout beyond expectations. The investment case also hinges on DMR-001 showing meaningful improvement over INCA033989 in non-Type 1 mutCALR ET or MF patients and proving Q4W tolerability and PK at doses that match an IV efficacy benchmark, yet INCA033989 already appears to have a 2-3 year head start and could capture much of the addressable market first. More broadly, the platform still lacks clinical validation, and even the cited field evidence shows endpoints such as VAF remain controversial while prior hematology programs like momelotinib struggled to persuade regulators despite some efficacy signals.